On September 9, Nuochengjianhua announced that ICP-B381, a new dual-antibody ADC drug targeting PSMA and STEAP1 developed independently by the company, was approved by the Drug Evaluation Center of the State Drug Administration to conduct clinical trials to treat solid tumors such as prostate cancer. This is the company's first dual-antibody ADC approved clinically, and the company's third innovative ADC drug to enter clinical trials.

On September 9, Nuochengjianhua announced that ICP-B381, a new dual-antibody ADC drug targeting PSMA and STEAP1 developed independently by the company, was approved by the Drug Evaluation Center of the State Drug Administration to conduct clinical trials to treat solid tumors such as prostate cancer. This is the company's first dual-antibody ADC approved clinically, and the company's third innovative ADC drug to enter clinical trials.